
Sign up to save your podcasts
Or


Lisa Salberg and Dr. Michael Ayers explore the rapidly evolving world of HCM treatment, from myosin inhibitors and clinical trials to AFib management and patient-centered care. The episode also dives into advocacy, drug safety concerns, and why personalized treatment strategies matter more than ever for people living with hypertrophic cardiomyopathy.
This conversation was recorded May 15, 2026.
By Hypertrophic Cardiomyopathy Association / Lisa Salberg5
88 ratings
Lisa Salberg and Dr. Michael Ayers explore the rapidly evolving world of HCM treatment, from myosin inhibitors and clinical trials to AFib management and patient-centered care. The episode also dives into advocacy, drug safety concerns, and why personalized treatment strategies matter more than ever for people living with hypertrophic cardiomyopathy.
This conversation was recorded May 15, 2026.

78,668 Listeners

37,657 Listeners

12,159 Listeners

112,187 Listeners

56,559 Listeners

16,393 Listeners

47,831 Listeners